United Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $619.4167.

A number of research analysts recently weighed in on the stock. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Bank of America increased their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. HC Wainwright increased their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $549.87 on Monday. United Therapeutics has a one year low of $272.12 and a one year high of $609.35. The company’s 50-day simple moving average is $568.23 and its 200 day simple moving average is $519.16. The firm has a market capitalization of $23.34 billion, a P/E ratio of 20.30, a PEG ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.63 EPS. On average, equities research analysts expect that United Therapeutics will post 26.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 614,543 shares of company stock valued at $346,728,395 in the last 90 days. 8.60% of the stock is currently owned by company insiders.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management grew its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC grew its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics during the fourth quarter valued at $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.